Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain.

The metabolism of xenobiotics in human brain constitutes a field of recent intensive research in relation to the potential implications in the pharmacological effect of drugs acting on the central nervous system. Cytochrome P450 enzymes (CYPs) play a crucial role in these metabolic pathways and the existence of functional CYP monooxygenases in brain is now well established. These enzymes are preferentially localized in the neuronal cells within the microsomal fraction and the inner membrane of mitochondria. Although low, the metabolism in situ could influence individual response to xenobiotics or produce reactive, toxic metabolites causing irreversible damage in the neuronal cells. The abundant presence of CYPs in selective cell populations within different regions of the brain has also suggested a role for these enzymes in brain physiology thus not restricted to xenobiotic-induced neurotoxicity. For instance, CYPs participate in the regulation of neurotransmitters and steroids and brain maintenance of cholesterol homeostasis. Recent advances support an additional role for these enzymes in the pathogenesis of psychiatric and neurodegenerative disorders such as depression, schizophrenia, and Alzheimer's and Parkinson's diseases. The characterization of brain CYP isoforms and their localization, the identification of their substrates and metabolic end-products will allow better understanding of the role of these enzymes in brain physiology, development and diseases.

[1]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[2]  I. Björkhem,et al.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain , 2006, Journal of internal medicine.

[3]  Volk,et al.  Testosterone Metabolism In Rat Brain Is Differentially Enhanced By Phenytoin‐Inducible Cytochrome P450 Isoforms , 1999, Journal of neuroendocrinology.

[4]  R. Lathe,et al.  Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone , 1997 .

[5]  M. Negishi,et al.  Regulation of cytochrome P450 (CYP) genes by nuclear receptors. , 2000, The Biochemical journal.

[6]  T. Bayer,et al.  Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300320-JLR200 , 2004, Journal of Lipid Research.

[7]  M. Boyd,et al.  A Frameshift Mutation and Alternate Splicing in Human Brain Generate a Functional Form of the Pseudogene Cytochrome P4502D7 That Demethylates Codeine to Morphine* , 2004, Journal of Biological Chemistry.

[8]  T. Slotkin Guidelines for developmental neurotoxicity and their impact on organophosphate pesticides: a personal view from an academic perspective. , 2004, Neurotoxicology.

[9]  S. Imaoka,et al.  Dopamine formation from tyramine by CYP2D6. , 1998, Biochemical and biophysical research communications.

[10]  F. Bergquist,et al.  Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: A new metabolic pathway? , 2001, Synapse.

[11]  R. Rawbone,et al.  Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. , 2000, Toxicology letters.

[12]  V. Ravindranath,et al.  Constitutive expression and localization of cytochrome P‐450 1A1 in rat and human brain: presence of a splice variant form in human brain 1 , 2005, Journal of neurochemistry.

[13]  J. Idle,et al.  The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[14]  M. Boyd,et al.  Expression of multiple forms of cytochrome P450 and associated mono-oxygenase activities in rat brain regions. , 1998, Biochemical pharmacology.

[15]  Ernest Hodgson,et al.  In vitro human phase I metabolism of xenobiotics I: Pesticides and related compounds used in agriculture and public health, may 2003 , 2003, Journal of biochemical and molecular toxicology.

[16]  V. Ravindranath,et al.  Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues , 2006, Expert opinion on drug metabolism & toxicology.

[17]  A. Somogyi,et al.  Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. , 1990, Life sciences.

[18]  H. Checkoway,et al.  Epidemiologic approaches to the study of Parkinson's disease etiology. , 1999, Epidemiology.

[19]  J. Schenkman,et al.  Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. , 2005, Archives of biochemistry and biophysics.

[20]  J. Yager,et al.  Tissue-specific synthesis and oxidative metabolism of estrogens. , 2000, Journal of the National Cancer Institute. Monographs.

[21]  S. Auriola,et al.  Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes , 2000, Archives of Toxicology.

[22]  Sharon Miksys,et al.  Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics , 2003, British journal of pharmacology.

[23]  P. Fritz,et al.  Distribution and Cellular Localization of Prostacyclin Synthase in Human Brain , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[24]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Shankar,et al.  NADPH cytochrome P-450 reductase in rat, mouse and human brain. , 1990, Biochemical pharmacology.

[26]  R. Tyndale,et al.  Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. , 2003, Molecular pharmacology.

[27]  C. Elger,et al.  Messenger RNA of steroid 21-hydroxylase (CYP21) is expressed in the human hippocampus , 2001, Neuroscience Letters.

[28]  F. Guengerich,et al.  Radical cation intermediates in N-dealkylation reactions. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  F Peter Guengerich,et al.  Cytochrome P450: What Have We Learned and What Are the Future Issues? , 2004, Drug metabolism reviews.

[30]  S. Creighton,et al.  Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Ceccatelli,et al.  Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the expression of cytochrome P450 1A1, the aryl hydrocarbon receptor, and the aryl hydrocarbon receptor nuclear translocator in rat brain and pituitary. , 2000, Toxicology and applied pharmacology.

[32]  R. Martins,et al.  Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.

[33]  R. Tyndale,et al.  Drug-metabolizing cytochrome P450s in the brain. , 2002, Journal of psychiatry & neuroscience : JPN.

[34]  F. Oesch,et al.  Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicity , 2006, Pharmacogenetics and genomics.

[35]  G. Siest,et al.  Subcellular distribution of cytochrome P-450 in the brain , 1986, Brain Research.

[36]  Anna M. Lee,et al.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein , 2006, British journal of pharmacology.

[37]  B. Stoffel‐Wagner Neurosteroid metabolism in the human brain. , 2001, European journal of endocrinology.

[38]  C. J. Omiecinski,et al.  Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  Eric A Newman,et al.  Glial Cells Dilate and Constrict Blood Vessels: A Mechanism of Neurovascular Coupling , 2006, The Journal of Neuroscience.

[40]  J M Guileyardo,et al.  cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Taimi,et al.  CYP2U1, a Novel Human Thymus- and Brain-specific Cytochrome P450, Catalyzes ω- and (ω-1)-Hydroxylation of Fatty Acids* , 2004, Journal of Biological Chemistry.

[42]  M. Eichelbaum,et al.  Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.

[43]  Yifu Deng,et al.  Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease , 2004, Annals of neurology.

[44]  C. Eckman,et al.  Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease* , 2004, Journal of Biological Chemistry.

[45]  C. Thompson,et al.  Cytochromes P450 in brain: function and significance. , 2001, Current drug metabolism.

[46]  M. Eichelbaum,et al.  Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.

[47]  J. Goldstein,et al.  Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs , 1999, Journal of biochemical and molecular toxicology.

[48]  A. Kappas,et al.  On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain , 1977, The Journal of experimental medicine.

[49]  L. Bertilsson,et al.  Relationship between personality and debrisoquine hydroxylation capacity , 1993, Acta psychiatrica Scandinavica.

[50]  J. Idle,et al.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. , 2003, Pharmacogenetics.

[51]  C. J. Omiecinski,et al.  Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. , 1993, Journal of toxicology and environmental health.

[52]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[53]  N. Alkayed,et al.  Cytochrome P450 in neurological disease. , 2004, Current drug metabolism.

[54]  P. Jenner,et al.  P450 enzymes and Parkinson's disease: The story so far , 1998, Movement disorders : official journal of the Movement Disorder Society.

[55]  K. Husgafvel‐Pursiainen,et al.  CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. , 2000, Pharmacogenetics.

[56]  M. Boyd,et al.  Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. , 2000, Biochemical pharmacology.

[57]  H. Kölsch,et al.  Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17β , 2001, Journal of Neural Transmission.

[58]  J. Kraner,et al.  Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). , 2001, Journal of analytical toxicology.

[59]  C. Gomez-Sanchez,et al.  Steroidogenic enzyme gene expression in the human brain , 2002, Molecular and Cellular Endocrinology.

[60]  I. Pikuleva CHOLESTEROL-METABOLIZING CYTOCHROMES P450 , 2006, Drug Metabolism and Disposition.

[61]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[62]  Xiaochao Ma,et al.  METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.

[63]  S. Shankar,et al.  Microsomal cytochrome P450 in human brain regions. , 1992, Biochemical pharmacology.

[64]  D. Kusewitt,et al.  In Situ Hybridization and Immunohistochemical Analysis of Cytochrome P450 1B1 Expression in Human Normal Tissues , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[65]  V. Hans,et al.  Characterization of the dehydroepiandrosterone (DHEA) metabolism via oxysterol 7α‐hydroxylase and 17‐ketosteroid reductase activity in the human brain , 2002, Journal of neurochemistry.

[66]  S. Imaoka,et al.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.

[67]  Schramm,et al.  Sex‐ and Age‐Specific Differences in Human Brain CYP11A1 mRNA Expression , 1999, Journal of neuroendocrinology.

[68]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[69]  Sharon Miksys,et al.  Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.

[70]  A. Gaedigk,et al.  CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? , 2005, Biochemical and biophysical research communications.

[71]  A. Williams,et al.  Cytochrome P450 1B1 mRNA in the human central nervous system. , 1998, Molecular pathology : MP.

[72]  M. Ames,et al.  Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. , 1977, Biochemical and biophysical research communications.

[73]  L. Sayre,et al.  Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[74]  Anna M. Lee,et al.  CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment , 2006, Neuropharmacology.

[75]  R. Pohjanvirta,et al.  Effect of TCDD on mRNA expression of genes encoding bHLH/PAS proteins in rat hypothalamus. , 2005, Toxicology.

[76]  R. Poulsom,et al.  Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[77]  I. Hindmarch Beyond the monoamine hypothesis: mechanisms, molecules and methods , 2002, European Psychiatry.

[78]  R. Tyndale,et al.  Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. , 1991, Molecular pharmacology.

[79]  S. Mellon,et al.  Neurosteroids: biochemistry and clinical significance , 2002, Trends in Endocrinology & Metabolism.

[80]  M. Boyd,et al.  Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. , 2000, Archives of biochemistry and biophysics.

[81]  K. Ukena,et al.  Novel brain function: biosynthesis and actions of neurosteroids in neurons , 2000, Neuroscience Research.

[82]  G. Tucker,et al.  Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[83]  R. Tyndale,et al.  The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics , 2004, Drug metabolism reviews.

[84]  Tetsuo Satoh,et al.  Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. , 2003, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[85]  R. Tyndale,et al.  Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[86]  K. Kreth,et al.  Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. , 2000, Biochemical pharmacology.

[87]  A. Llerena,et al.  Low frequency of CYP2D6 poor metabolizers among schizophrenia patients , 2007, The Pharmacogenomics Journal.

[88]  J. Gustafsson,et al.  Regional Distribution of Cytochrome P‐450 in the Rat Brain: Spectral Quantitation and Contribution of P‐450b,e and P‐450c,d , 1988, Journal of neurochemistry.

[89]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[90]  D. Zeldin,et al.  Variability of CYP2J2 Expression in Human Fetal Tissues , 2006, Journal of Pharmacology and Experimental Therapeutics.

[91]  A. Beaudet,et al.  Vitamin E protects hypothalamic beta-endorphin neurons from estradiol neurotoxicity. , 1992, Endocrinology.

[92]  P. Wedlund,et al.  Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[93]  E. Hodgson In vitro human phase I metabolism of xenobiotics I: Pesticides and related chemicals used in agriculture and public health, September 2001 , 2001, Journal of biochemical and molecular toxicology.

[94]  C. J. Omiecinski,et al.  Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNAs in the rat brain. , 1993, Molecular pharmacology.

[95]  M. Boyd,et al.  Characterization of a phenobarbital-inducible cytochrome P-450, NADPH-cytochrome P-450 reductase and reconstituted cytochrome P-450 mono-oxygenase system from rat brain. Evidence for constitutive presence in rat and human brain. , 1992, The Biochemical journal.

[96]  C. Bouras,et al.  Cytochrome P-450 activities in human and rat brain microsomes , 2000, Brain Research.

[97]  T. Baillie,et al.  Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. , 1987, Science.

[98]  Y. Funae,et al.  CYP2D in the brain. , 2003, Drug metabolism and pharmacokinetics.

[99]  M. Boyd,et al.  Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. , 2002, Brain research. Molecular brain research.

[100]  G. Gordon Gibson,et al.  Introduction to Drug Metabolism , 1986, Springer US.

[101]  R. Tyndale,et al.  Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. , 2000, Journal of clinical psychopharmacology.

[102]  A. Somogyi,et al.  Precipitated withdrawal following codeine administration is dependent on CYP genotype. , 2001, European journal of pharmacology.

[103]  C. Caltagirone,et al.  Genetic correlates of behavioral endophenotypes in Alzheimer disease: Role of COMT, 5-HTTLPR and APOE polymorphisms , 2006, Neurobiology of Aging.

[104]  H. Sasano,et al.  Aromatase in the human central nervous system , 1998, Clinical endocrinology.

[105]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[106]  Christophe Tzourio,et al.  CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease , 2004, Annals of neurology.

[107]  K. Reuhl,et al.  Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum , 2003, Archives of Toxicology.

[108]  M. Ingelman-Sundberg,et al.  Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. , 2004, Biochemical and biophysical research communications.

[109]  C. Elger,et al.  Expression of cytochrome P450scc mRNA in the hippocampus of patients with temporal lobe epilepsy. , 1999, Neuroreport.

[110]  G. Murray,et al.  Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. , 1998, Biochemical pharmacology.

[111]  E. Masliah,et al.  Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells. , 2003, Gene Expression.

[112]  G. Siest,et al.  Dextromethorphan O-demethylase activity in rat brain microsomes , 1995, Neuroscience Letters.

[113]  T. Yokoi,et al.  Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. , 2004, Drug metabolism and pharmacokinetics.

[114]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[115]  D. Rozman,et al.  Mammalian cytochromes P450--importance of tissue specificity. , 2007, Biochimica et biophysica acta.

[116]  S. Imaoka,et al.  Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. , 2004, Endocrinology.

[117]  M. Juchau,et al.  Expression of cytochrome P450RAI (CYP26) in human fetal hepatic and cephalic tissues. , 1998, Biochemical and biophysical research communications.

[118]  L. Thal,et al.  Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.

[119]  T. Hicks,et al.  The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain , 2006, Progress in Neurobiology.

[120]  H. Issaq,et al.  Nicotine metabolism and CYP2D6 phenotype in smokers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[121]  S. Khuder,et al.  A meta-analysis of Parkinson's disease and exposure to pesticides. , 2000, Neurotoxicology.

[122]  E. Sellers,et al.  Interactions of amphetamine analogs with human liver CYP2D6. , 1997, Biochemical pharmacology.

[123]  R. Tyndale,et al.  Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. , 2000, Biochemical pharmacology.

[124]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[125]  G. Murray,et al.  Cytochrome P450 CYP3A5 in the human anterior pituitary gland , 1995, FEBS letters.

[126]  W. Miller Disorders of Androgen Synthesis – from Cholesterol to Dehydroepiandrosterone , 2005, Medical Principles and Practice.

[127]  W. J. Brooks,et al.  Astrocytes as a primary locus for the conversion MPTP into MPP+ , 1989, Journal of Neural Transmission.